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Abstract In many parts of the world, mostly low- and middle-income countries, timely diagnosis and repair of
congenital heart diseases (CHDs) is not feasible for a variety of reasons. In these regions, economic growth has
enabled the development of cardiac units that manage patients with CHD presenting later than would be ideal,
often after the window for early stabilisation – transposition of the great arteries, coarctation of the aorta – or for
lower-risk surgery in infancy – left-to-right shunts or cyanotic conditions. As a result, patients may have suffered
organ dysfunction, manifest signs of pulmonary vascular disease, or the sequelae of profound cyanosis and
polycythaemia. Late presentation poses unique clinical and ethical challenges in decision making regarding
operability or surgical candidacy, surgical strategy, and perioperative intensive care management.
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THERE IS A PAUCITY OF EVIDENCE-BASED LITERATUREon most aspects of late-presenting CHD.Similarly, guidelines on operability in infants
and children with late CHD are scarce. This article
reviews available published information and common
practices of cardiologists, surgeons, and intensivists
from across the globe who routinely manage late-
presenting CHD. Units with a large case load of late
CHD are typically those that can least afford
expensive rescue strategies, and thus most practices
are based on less expensive therapies. Finally, the
management of late CHD will remain an evolving
story as more data and experience accumulate.
Background
Congenital cardiac abnormalities are the most common
of all birth defects and are responsible for the majority of
deaths due to congenital abnormalities. It is estimated
that, worldwide, approximately one million children
are born annually with CHD. Of these, the majority
are born in low- and middle-income countries where,
regardless of the optimal strategy, surgery in early
infancy is not always feasible.1
With improving economic conditions and
increasing availability of paediatric cardiac care,
many infants, older children, and adults who would
previously not have had access to these services
present for cardiac care for the ﬁrst time relatively
late in their natural history, with increased risk of
perioperative morbidity and mortality, or even
inoperability. The challenge lies in eliminating
late CHD as a risk factor for early mortality and
minimising morbidity using cost-effective strategies.
With reduction in early mortality, there has been a
shift towards treatment modalities that are also
associated with better long-term quality of life.
In this article, potential strategies and guidelines
for the management of late-presenting CHD will be
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discussed. This is a broad topic with limited sup-
portive literature. The recommendations are therefore
based upon the available published literature, as well
as opinions of surgeons, cardiologists, and other
care-givers from low- and middle-income countries
who deal with children presenting with late CHD.
The focus of this review is on commonly encountered
clinical scenarios that pose difﬁculties in decision
making.
What is “late-presenting CHD” and why does
it occur?
A detailed literature search does not yield a clear
deﬁnition of late CHD. Most surgeons, cardiologists,
and intensivists would concur that late CHD should
not be confused with adult CHD and has no speciﬁc
relation to age at presentation. Instead it would
appear that late CHD refers to presentation late in the
natural history of the speciﬁc cardiac defect, with consequent
transient or irreversible haemodynamic and pathologic
alterations that would impact the medical and surgical
approach, risk, and outcome. Thus, a 10-year-old child
presenting with a moderate-sized atrial septal defect
may not be considered late, but a newborn with
transposition of great arteries and intact ventricular
septum presenting at 1 month of age with cardio-
vascular collapse would be considered to be a late
presentation. The late presentation of CHD occurs
owing to a variety of reasons: late diagnosis and
referral; limited resources and infrastructure, or geo-
graphic factors precluding timely diagnosis and
transfer to a cardiac centre; and low levels of aware-
ness and inappropriate medical advice. Some or all of
these factors are routinely encountered in low- and
middle-income countries; hence, late presentation is
common.1–4
Consequences of late-presenting CHD
The physiological and pathological consequences of
late presentation vary according to the type of lesion
and associated circulatory abnormalities and may be
broadly grouped as follows:
∙ Newborns with critical, duct-dependent CHD
including coarctation of the aorta or pulmonary
atresia, or those with CHD dependent on intra-
cardiac mixing such as transposition of great
arteries, typically present with circulatory collapse,
and varying degrees of multiorgan dysfunction
adversely impacting surgical outcomes.5,6
∙ Older infants and children with chronic and
relatively stable CHD associated with left-to-right
shunts and pulmonary over-circulation, including
large ventricular septal defects, double-outlet right
ventricle with ventricular septal defect, or truncus
arteriosus, may present with other consequences.
These include frequent respiratory infections,
cachexia, and pulmonary hypertension.
∙ Chronic cyanosis in the setting of unoperated
tetralogy of Fallot, single ventricle with pulmonary
obstruction, or Eisenmengers syndrome can lead
to polycythaemia with or without disseminated
intravascular coagulopathy, hepatic or renal dys-
function, or stroke.
∙ Unoperated valvular disease or indeed any intra-
cardiac defect, particularly in the setting of poor
nutrition and adverse environmental factors, can
signiﬁcantly increase the risk of endocarditis.
Presentation may be with acute circulatory collapse
due to acute onset of severe valvular regurgitation
or with manifestations of pulmonary or systemic
embolisation. Neurologic complications from
brain abscesses are also not uncommon.
Late-presenting CHD associated with left-to-
right shunts
Left-to-right shunts including atrial septal defects,
ventricular septal defects, and patent ductus arter-
iosus are among the most common forms of CHD
that present late, resulting in varying degrees of
pulmonary hypertension. With timely surgery,
mortality and morbidity for these defects is very
low. The challenge lies in deciding operability
and, if operable, ensuring good-quality long-term
survival.
There is little consensus as to the deﬁnition of
operability in terms of echocardiographic data or
catheterisation-derived pulmonary vascular resistance
index measurements.7–11 Similarly, there is wide
variability in the surgical approach. In general, cur-
rent recommendations are relatively conservative – a
pulmonary vascular resistance index cut-off of <6
Wood units m2 7 (Table 1). However, some institu-
tions have offered surgery for patients with a pul-
monary vascular resistance index up to 15 Wood
units/m2.12–16 Surgical strategies to overcome perio-
perative pulmonary hypertensive crises have varied
from the use of a decompressive atrial communication
to valved patch closure of a ventricular septal defect
or atrial septal defect (Table 2), or pulmonary artery
banding with excellent early survival.12–19 Talwar
et al15 reported excellent early and midterm out-
comes with unidirectional valved patch with regres-
sion of pulmonary hypertension in the midterm;
however, there have also been reports of worsening
pulmonary hypertension in the longer term.16 It
would appear that a standardised approach to early
assessment and close postoperative follow-up would
ensure that surgery is offered appropriately and not to
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patients with established pulmonary vascular disease,
thereby offering the best possible outcomes for these
high-risk patients.11,20–22
More complex cardiac malformations such as
double-outlet right ventricle, transposition of great
arteries with ventricular septal defect, or truncus
Table 1. Preoperative evaluation of paediatric patients with congenital systemic-to-pulmonary shunts – ﬁndings that may indicate a
favourable or unfavourable response to correction of the cardiac defect.
Parameters Favourable Unfavourable
History
Congestive heart failure/pulmonary congestion Present Absent
Failure to thrive Yes No
Use of decongestive medication Yes No
Physical examination
Dyspnoea Present/overt Mild/absent
Peripheral oxygen saturation (%)* >95 <90
Chest X-ray
Size of the heart Enlarged Hypertrophied
Pulmonary vascular marking Prominent Decreased distal marking
Congestion Present Absent
Transthoracic echocardiography
Direction of ﬂow across the communication Left-to-right or bidirectional,
but predominantly left-to-right
Bidirectional, predominantly
right-to-left
Size of left cardiac chambers (post-tricuspid valve shunts) Enlarged Not enlarged
Pulmonary-to-systemic blood ﬂow ratio (Qp∶Qs) >3:1 <2:1
Cardiac catheterisation
Pulmonary vascular resistance index (Wood units m2)** <6.0 (preferably <4.0) >8.0
Pulmonary-to-systemic vascular resistance ratio (PVR/SVR) <0.3 >0.5
PVR= pulmonary vascular resistance; SVR= systemic vascular resistance
Modiﬁed from Lopes et al, “Guidelines and Consensus. Repair of congenital heart disease with associated pulmonary hypertension in children: what are
the minimal investigative procedures?”7.
*Basal saturations of 90–95% should also be reviewed case-by-case
**Pulmonary vascular resistance index 4–8 should be individualised or managed case-by-case
Table 2. Summary of results with different surgical procedures in ventricular septal defects and severe pulmonary hypertension.
Author (year) Study type
Patient group, age in
years, and baseline
parameters
Type of surgical
procedure Outcomes Follow-up
Novick et al12 Case series N= 18, 5.7± 3.9, baseline
PVRI= 11.4W U
Flap valve double
VSD patch
No early death, 1 late
death at 9 months
No cath data
Hui-Li Gan et al13 Comparative
study
UVP (n= 195) and
NVP (n= 681)
Baseline PVRI
10.6± 4.21 versus
8.4± 4.48
UVP versus NVP UVP provides no
beneﬁt to early and
long-term survival
Mean follow-up of 9.2± 4.92
years, steady attrition, but no
survival difference
Zhang et al14 Case series N= 27, mean
age= 15± 5.6 years,
PVRI 15.2± 3.8
Unidirectional
monovalve
homologous aortic
patch
Early death 2, no late
death
5 months to 10 years, long-term
result was satisfactory
Talwar et al15 Case series N= 13, mean
age= 8.5± 4.4 year,
PVRI= 10± 2.1,
SPAP= 96.2± 13.6
Unidirectional
valve patch closure
No early or late
death
Repeat PVRI= 5.8± 2.1
Sridhar et al16 Case series N= 30, mean age
9.8± 2.69 years,
PVRI= 11.39± 1.6
Cruciate
fenestration in
ventricular septal
defect patch
No early death, one
late death
Persistent PAH and worsening
clinical status, follow-up
PVRI= 15.3± 1.3 (N= 11)
Ming-Tai and
Lin et al17
Case series N= 8, SPAP= 119± 9 Pulmonary artery
banding
No early or late
death
Functional class improvement
NVP= non-valve patch; PAH= Pulmonary artery hypertension; PVRI= pulmonary vascular resistance index; SPAP= systolic pulmonary artery pres-
sure; UVP= unidirectional valve patch; VSD= ventricular septal defect; WU=wood unit
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arteriosus presenting late pose even greater challenges
in deciding surgical candidacy. Current consensus
for these conditions is that clinical criteria such as
baseline oxygen saturation and responsiveness to
supplemental oxygen, as well as radiologic criteria
suggestive of pulmonary over-circulation, may help
to deﬁne operability.23
Late-presenting tetralogy of Fallot and
associated physiology
Tetralogy of Fallot is the most common cyanotic
heart defect outside the neonatal period. Nonetheless,
an extensive literature search yielded only case reports
of the polycythaemic hypercyanotic tetralogy of
Fallot, with search terms such as late tetralogy of
Fallot, hypercyanotic tetralogy of Fallot, bleeding
and tetralogy of Fallot, intracranial bleeds and
tetralogy of Fallot, endotracheal bleeding, and
collaterals in tetralogy of Fallot. The following
recommendations represent consensus opinion from
multiple high-volume units across low- and middle-
income countries that have signiﬁcant experience in
managing patients with tetralogy of Fallot with long-
standing cyanosis and polycythaemia.
Complete repair during the ﬁrst year of life is the
surgical approach of choice for patients with tetralogy
of Fallot in high-income countries. In low- and
middle-income countries, however, patients with
tetralogy of Fallot commonly present for the ﬁrst time
during childhood, adolescence, or even late adult-
hood.24 Some would be natural survivors of so-called
“good anatomy tetralogy of Fallot” with minimal
cyanosis and therefore manifest limited consequences
of chronic cyanosis. Most patients, however, are
markedly cyanotic and may manifest the deleterious
sequelae of chronic polycythaemia with hyperviscos-
ity and varying degrees of consumptive coagulo-
pathy. In the absence of anatomic limitations such as
signiﬁcant hypoplasia of the branch pulmonary
arteries, a deﬁnitive complete repair is the goal for all
patients. A good surgical outcome in these patients is
dependent on the following: detailed preoperative
evaluation that dictates the speciﬁc preoperative
preparation required; and careful customised cardio-
pulmonary bypass strategy, surgical approach, and
perioperative care. We recommend the following.
Preoperative evaluation
∙ CT angiogram to assess pulmonary artery anatomy
and delineate aortopulmonary collaterals, as these
can signiﬁcantly affect cerebral protection during
surgery, and can predispose to major postoperative
pulmonary bleeds. A decision to embolise these
collaterals preoperatively is based on size and
distribution.
∙ Detailed haematological work-up, with emphasis
on coagulation proﬁle, platelet count, and func-
tion. Profound polycythaemia secondary to long-
standing cyanosis can lead to impaired coagulation
and thrombocytopaenia.
∙ Detailed assessment of liver and kidney function.
∙ CT scan/MRI of the brain to exclude occult
haemorrhage, recent or old infarcts, healed or
active brain abscesses, and porencephaly.
Preoperative preparation
∙ Cardiac catheterisation: signiﬁcant aortopulmon-
ary collaterals should be occluded in the catheter-
isation laboratory, with the operating room in
readiness for immediate surgery in the event of
signiﬁcant desaturation.
∙ Haematologic: isovolaemic phlebotomy should be
considered in order to reduce the haematocrit to
below 60%. The evidence for or against this practice
is equivocal. Preoperative folic acid supplementation
may improve thrombocytopaenia if surgery is not
imminent. If there is persistent thrombocytopaenia
and an unacceptable risk of bleeding associated with
cardiopulmonary bypass, a staged approach using a
modiﬁed Blalock–Taussig shunt in the ﬁrst instance
can be considered.
∙ Blood bank: adequate stocks of blood and blood
products should be kept in readiness.
Intraoperative approach
∙ Nasal intubation or naso-gastric tubes should be
avoided to prevent adenoidal haemorrhage.
∙ A higher-than-usual haematocrit is maintained on
cardiopulmonary bypass to ensure adequate perfu-
sion pressures.
∙ Normothermic or mildly hypothermic bypass is
used to avoid further exacerbating impaired
coagulation.
∙ Increased left atrial return, due to small collaterals,
is managed with efﬁcient suction rather than
reducing pump ﬂows.
∙ Excessive infundibular resection is avoided.25 The
transannular patch should be limited and some
residual dynamic gradient may be desirable at the
end of repair.25
∙ Epicardial or transoesophageal echocardiography is
used for assessing repair.
∙ Elective primary pulmonary valve replacement is
often needed/preferred in adults to avoid free
pulmonary regurgitation following complete repair.
∙ Meticulous haemostasis is achieved.
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Postoperative care
Bleeding and a low cardiac output state are the
problems most commonly encountered in the ICU.
Postoperative bleeding, particularly pulmonary or
intracranial, remains an important cause of mortality
in this population. Although diastolic right
ventricular dysfunction is common after tetralogy
of Fallot repair, the postoperative course of
late-presenting patients may also be complicated by
systolic left ventricular dysfunction due to chronic
hypoxaemia. The following anticipatory guidelines
are recommeded:
∙ Avoidance of haemodilution should be a routine
aspect of postoperative management to avoid low
systemic vascular resistance and hypotension. We
suggest that haematocrit is ideally maintained at
40–45%.
∙ Right ventricular diastolic dysfunction is to be
anticipated. Measures to improve right ventricular
function include maintaining adequate central
venous pressure of 10–12mmHg; ventilation
with low mean airway pressures, or early extuba-
tion, unless there is a concern for reperfusion
injury or pulmonary haemorrhage; and avoidance
of β-adrenergic catecholamines. In terms of
vasoactive support, a combination of milrinone
and noradrenaline (norepinephrine) is considered
effective.
∙ Mechanical ventilation must be individualised
depending on the pulmonary status, particularly
in the presence of endo-bronchial bleeding, and
right and left ventricular function. Higher-than-
usual levels of positive end expiratory pressure may
sometimes be required to assist the lungs and left
heart. It should be noted that positive end
expiratory pressure titration should be very cau-
tious, as the increase in mean airway pressure may
increase right ventricle afterload, which already has
severe diastolic dysfunction, and therefore worsen
the haemodynamic state.
∙ Chronic polycythaemia increases the risk of post-
operative bleeding from surgical sites, as well as
internal organs. Patients should be closely mon-
itored for signs of bleeding, and fresh frozen
plasma, platelets, and coagulation factors should
be used to optimise coagulation status in the
presence of bleeding.
∙ Persistent endotracheal bleeding warrants urgent
investigation. In the absence of coagulopathy,
additional collaterals or a signiﬁcant large addi-
tional or residual ventricular septal defect should
be ruled out.
With these perioperative measures in place, dis-
charge mortality can be reduced to <1%.
The late presentation of single-ventricle
physiology with polycythaemia
This is a complex scenario, and a full discussion is
beyond the scope of this article. The key considera-
tion for these patients is candidacy for a primary
Fontan operation. This decision requires careful
multidisciplinary evaluation of systemic ventricular
function, atrioventricular valve regurgitation, and
collateral circulation. These patients are often pro-
foundly cyanosed and their preoperative preparation
is similar to that for the polycythaemic tetralogy of
Fallot. During the postoperative phase, there is a
tendency for protracted effusions to develop, parti-
cularly late-onset pericardial effusions requiring
drainage. Early survival in most units is excellent and
parallels the staged Fontan. However, owing to
inadequate follow-up data, long-term outcomes
remain uncertain.
The late-presenting newborn with critical
CHD
Critical heart defects commonly missed at discharge
from the maternity wards include transposition of
great arteries with intact ventricular septum, coarc-
tation of the aorta, and total anomalous pulmonary
venous connection – all of which are treatable with
low-risk corrective surgery.26 Approximately 40% of
those discharged present with cardiovascular collapse,
making subsequent management challenging, and
signiﬁcantly increasing perioperative morbidity and
mortality.5,27
Before any intervention, the work-up after initial
resuscitation and stabilisation of newborns presenting
with critical CHD should include assessment of all
organ systems and, where available, MRI of the brain
to rule out injury related to hypoxaemia or
hypoperfusion.28
The sick newborn with coarctation or near-total
arch interruption often has severe biventricular dys-
function, as well as multiorgan dysfunction and often
coexistent sepsis. Many units now would do a tem-
porising catheter-based balloon dilatation of the
coarctation, which usually results in relatively rapid
recovery and >95% chance of discharge.29,30 The
infant is closely followed up and re-admitted for an
elective surgical repair as and when there is
recoarctation.
Transposition of the great arteries with intact ventricular
septum
The sick neonate with transposition of great arteries and
intact interventricular septum presenting with circula-
tory collapse and end-organ dysfunction usually has
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cardiovascular compromise owing to inadequate inter-
circulatory mixing and/or associated Gram-negative or
fungal sepsis – in 20–30% of cases. In these patients,
stabilisation procedures may include a temporising
high-risk balloon atrial septostomy or blade septectomy,
if the septum is very thickened, interatrial stent, or
patent ductus arteriosus stent.31,32
The major challenge in decision making in these
cases relates to the optimal timing of surgery and
then the most appropriate initial operation in a
patient with a potentially unprepared left ventricle.
This decision is usually taken on a case-by-case basis.
In Asia, where the problem of perioperative multi-
resistant Gram-negative sepsis – a major risk factor
for mortality – is signiﬁcant,33 many units are
increasingly opting to treat the sepsis, discharge, and
then review, rather than subjecting an infant with
partially treated sepsis to cardiopulmonary bypass,
and then having to manage fulminant sepsis in the
postoperative period.
As far as we are aware, most surgeons in low- and
middle-income settings would prefer to perform an
arterial switch as the most physiologic procedure for
all infants with transposition of great arteries with
intact interventricular septum.34–41 A primary
arterial switch is offered regardless of age when the
left ventricle is considered prepared or non-regressed.
However, when the left ventricle is considered to be
regressed, there is debate as to whether one should
opt for a primary arterial switch or a two-stage switch
after “rapid” left ventricle preparation with a pul-
monary artery band. Several criteria for regression of
the left ventricle in late-presenting transposition of
great arteries have been proposed:
∙ Echocardiographic parameters: left ventricle shape –
“banana shaped”; interventricular septum – moving
with right ventricle rather than left ventricle; left
ventricle posterior wall thickness – <3.0mm; left
ventricle mass <35gm/m2; low left ventricle end
diastolic volume; and non-quantitative assessment of
the left ventricle.
∙ Haemodynamic parameters – left ventricle/right
ventricle pressure ratio <0.7.
∙ Intraoperative response to trial of pulmonary artery
banding.
Today, there is sufﬁcient level 2 evidence to indi-
cate that a primary arterial switch can be performed
until 8 weeks of age with outcomes comparable to
those of earlier repair.39 Most large-volume units in
low- and middle-income settings would still prefer a
delayed primary arterial switch in infants, even up to
3 months of age in a borderline regressed left ven-
tricle, to a two-stage switch. The rapid two-stage
switch is no longer popular even although one of the
early series from India reported acceptable out-
comes.42 This is because the ﬁrst stage of the
two-stage operation is often followed by a highly
unpredictable and stormy ICU course. The relatively
inexperienced medical and nursing staff of many of
the ICUs in low- and middle-income settings prefer
to manage the more predictable course of post-
operative left ventricle failure following a late pri-
mary arterial switch (Table 3). There are no easy
solutions, and the issue remains an evolving story as
low- and middle-income countries witness steady
improvements in intraoperative strategies, myo-
cardial protection, and postoperative intensive care.
Beyond 3 months of age, most units would offer
a low-morbidity atrial switch – Senning operation –
with a loose pulmonary artery band for possible
future conversion to an arterial switch. If the left
ventricle is still prepared after 3 months, then a
cardiac catheterisation is done for further evaluation.
The usual causes of left ventricle preparedness beyond
3 months of age are a large patent ductus arteriosus,
large aortopulmonary collaterals, left ventricular
Table 3. Late primary arterial switch experience with mortality and mechanical circulatory support (MCS) requirement.
Authors (year) Cohort Mortality MCS
Dabritz et al35 No early group
Late group (28–71 days)
Late group 0% Late group 0%
Kang et al36 275 (<21 days)
105 (21–185 days)
Early group 5.5%
Late group 3.8%
Early group 3.6%
Late group 5.7%
Sarris37 375 (<21 days)
52 (older than 4 weeks, 36 were older than 8 weeks)
Early group 3%
Late group 2%
None
Ismail et al38 64 (<21 days)
27 (>21 days, Mean age 37± 17 days)
Early group 3.1%
Late group 7.4%
Early group 0%
Late group 3.7%
Edwin et al39 16 (<21 days)
6 (31–66 days)
Early group 6.3%
Late group None
Early group 6.3%
Late group 33.3%.
Ma et al40 109 (> 30 days) 78 (primary arterial switch )
median age 1.9 months/31 (two-stage arterial switch)
2.65% (primary arterial switch)
9.7% (two-stage arterial switch)
None
Bisoi et al41 109 (42 days–8 years) Early death (8.2%)
Late death (1.8%)
20%
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outﬂow tract obstruction, and pulmonary hypertension.
In the event of pulmonary hypertension, an arterial
switch is offered only if the pulmonary hypertension
appears reversible. These infants often need periopera-
tive management of both left ventricular dysfunction
and pulmonary hypertension. In the presence of
signiﬁcant pulmonary vascular disease, a palliative
Senning procedure with a limited atrial septal defect is a
better option to relieve severe cyanosis.43
Obstructed total anomalous pulmonary venous connection
Obstructed total anomalous pulmonary venous
connection presenting in late infancy constitutes a
surgical emergency needing emergent repair. A
collapsed baby should be rushed to the operating
room as soon as possible without waiting for attempts
at preoperative stabilisation. Postoperatively, these
infants often have profound low output owing to a
non-complaint left atrium and left ventricle, as well
as pulmonary hypertension. Surgical strategies to
address this include leaving a decompressive patent
foramen ovale in the presence of severe pulmonary
hypertension and deferred sternal closure.
The postoperative low cardiac output state and
pulmonary hypertension
Delayed surgery is often accompanied by severe but
often transient postoperative low cardiac output state
owing to systemic ventricular or biventricular dys-
function. The typical features of this have been well
characterised by Wernovsky et al.44 In low- and
middle-income countries, the availability of extra-
corporeal support and adjunctive therapies such
as inhaled nitric oxide is typically very limited.
Management is based on conventional multimodal
practices, namely preload augmentation, appropriate
inotropy, and most importantly, aggressive afterload
reduction. Surgical strategies include delayed sternal
closure, intraoperative placement of a peritoneal dia-
lysis catheter in infants with anticipated low cardiac
output state, and, for patients with severe pulmonary
hypertension or right ventricle diastolic dysfunction,
a decompressive patent foramen ovale.
Adjuvant therapies include normalising ionised
calcium levels, physiologic doses of hydrocortisone,
and replacement thyroxine in documented hypo-
thyroidism. Owing to the sheer burden of late CHD,
plus economic and resource constraints, great efforts
are taken to avoid mechanical circulatory support.
Measures to reduce metabolic demand include
analgesia, sedation, muscle relaxation, and targeted
temperature control. Ventilatory support, appro-
priate use of positive end expiratory pressure, and
non-invasive ventilation are important therapies used
to improve afterload in systemic ventricular dys-
function with increased end diastolic pressures.44–48
In high-risk patients, such as those after a delayed
arterial switch operation, sternal closure, and even
extubation should be carefully timed events. In
principle, a common sense approach to do “only one
thing at a time” – for example, waiting for a period of
stability after chest closure before weaning sedation, or
weaning inotropes after extubation – should be
applied.
CHD-related pulmonary hypertension has been
extensively reviewed elsewhere.7–9,21,22,49 The inci-
dence of postoperative pulmonary hypertension is
much higher in late-presenting CHD.7 Current
consensus does not favour routine use of pulmonary
artery catheters or vasodilator therapy. The main
focus is on avoidance of triggers of pulmonary
hypertensive crises including pain, agitation,
hypercarbia, acidosis, high or low lung volumes, and
pre-emptive management of the low cardiac output
state with milrinone. An acute crisis may be managed
with inhaled nitric oxide or inhaled prostacyclin
when available7 and a single dose of sildenaﬁl is
recommended when weaning off nitric oxide.50
Alternatively, after the crisis is aborted with ade-
quate ventilation, intravenous sildenaﬁl or bosentan
or both may be used. After pulmonary hypertensive
crises, a detailed evaluation should be done to exclude
residual defects causing pulmonary hypertension.
Ethical and moral dilemmas
With improved cardiac care and better economic
growth, increasing numbers of neonates and infants,
particularly those with late transposition of great
arteries with intact interventricular septum and
left-sided obstructive lesions who present in actual
or pending circulatory collapse, are being offered
surgery with increasing survival. However, just as
for CHD globally, the importance of good-quality
survival is of paramount importance, and a signiﬁcant
proportion of late-presenting patients in low- and
middle-income countries already have pre-existing or
evolving neurologic injury detectable on clinical
examination or neuro-imaging before undergoing
surgery. This poses an important ethical challenge in
a setting where neither the family nor society can
necessarily afford to take on the burden of signiﬁcant
neurologic disability.
Summary
We note the following conclusions or take-home
messages:
∙ Late CHD is an increasing entity seen with
burgeoning economic growth.
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∙ Ideally, late presentation should affect a minority
and not the majority, and should be eliminated
as a risk factor for early surgical mortality and
morbidity.
∙ Unambiguous guidelines for operability and
management would be ideal but difﬁcult to
formulate.
∙ Surgery that is very likely to have adverse long-
term outcomes – for example, closing a ventricular
septal defect in a patient with severe pulmonary
hypertension – should be avoided.
∙ A more conservative approach to operability in the
presence of pulmonary hypertension – pulmonary
vascular resistance index <6, preferably <4 – is
recommended.
∙ Patients with polycythaemic tetralogy of Fallot can
have excellent early outcomes with judicious
perioperative planning.
∙ There is reasonable evidence to support that a
primary arterial switch operation can be safely
performed at up to 8 weeks of age, and potentially
as late as 3 months of age if there is appropriate
institutional experience and infrastructure.
∙ Severe low cardiac output state and/or pulmonary
hypertension often complicate the postoperative
course in late CHD. Attempts should be made to
manage these using standard modalities and
meticulous intensive care, and avoiding expensive
strategies such as mechanical circulatory support or
inhaled nitric oxide.
∙ Many practices will be validated only by midterm
or long-term follow-up of survivors, with sugges-
tions and recommendations requiring periodic
review over time.
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